Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post by Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center on X, adding:
“What is resectable stage III NSCLC?
It is good to have such guidelines but very important point that is missed in this is ‘potentially resectable’ depends upon ‘potential’ (experience and expertise) of Surgeon and back up team for post op Care and access to Immunotherapy drugs.
So it is not a straightforward decision and guidelines should include ‘learning curve’ and ‘access to Drugs’ as important factors before such decisions are made .”
Quoting Stephen Liu’s post:
“Consensus definition on resectability of stage III NSCLC from EORTC published on The Lancet Respiratory Medicine. Current consensus is that N3 or bulky N2 is unresectable but multi-station N2 remains potentially resectable. Does not lend itself perfectly to a flowchart given heterogeneity.”
Title: Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
Authors: Anne-Marie C. Dingemans, Isabelle Opitz, Alessandro Brunelli, Jordi Remon, Lizza E. L. Hendriks, John Edwards, Corinne Faivre-Finn, Noemi Reguart, Egbert F. Smit, Antonin Levy, David Sanchez-Lorente, Juan Carlos Trujillo, Andrea R. Filippi, Konstantinos Stathopoulos, Torsten G. Blum, Matthias Guckenberger, Sanjay Popat, Riccardo De Angelis, Paul Hofman, Jan von der Thüsen, Koen J. Hartemink, René H. Petersen, Enrico Ruffini, Chris Dickhoff, Ilias Houda, Elena Prisciandaro, Dirk De Ruysscher, Jules Derks, Idris Bahce, Alessio Mariolo, Benjamin Besse, Eleni Xenophontos, Niccolo Giaj Levra, Paul van Schil, Mariana Brandão, Thierry Berghmans
Read the Full Article.
Other Articles Featuring Amol Akhade and Stephen Liu on OncoDaily.